Ablynx Nv (OTCMKTS:ABLYF) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research note issued to investors on Wednesday. The firm presently has a $25.00 target price on the stock. Zacks Investment Research‘s price objective indicates a potential upside of 7.99% from the company’s current price.

According to Zacks, “Ablynx NV is a biopharmaceutical company which engaged in the development of Nanobodies (R) proprietary therapeutic proteins based on single-domain antibody fragments. The company also discovers and develops therapeutic for inflammation, haematology, immuno-oncology, oncology and respiratory disease. Ablynx NV is headquartered in Ghent, Belgium. “

Separately, Bank of America Corporation began coverage on shares of Ablynx Nv in a research report on Friday, November 10th. They issued a “buy” rating and a $26.00 target price on the stock.

Shares of Ablynx Nv (OTCMKTS:ABLYF) traded up $0.45 on Wednesday, hitting $23.15. 250 shares of the stock traded hands, compared to its average volume of 1,866. Ablynx Nv has a 12 month low of $9.75 and a 12 month high of $50.00.

TRADEMARK VIOLATION WARNING: “Ablynx Nv (ABLYF) Upgraded at Zacks Investment Research” was originally posted by American Banking News and is owned by of American Banking News. If you are viewing this article on another publication, it was illegally stolen and reposted in violation of United States & international trademark and copyright legislation. The original version of this article can be viewed at https://www.americanbankingnews.com/2017/11/22/ablynx-nv-ablyf-upgraded-at-zacks-investment-research.html.

Ablynx Nv Company Profile

Ablynx NV, a biopharmaceutical company, develops Nanobodies that is a proprietary therapeutic protein based on single-domain antibody fragments for the treatment of various diseases. The company develops products in various therapeutic areas, such as inflammation, hematology, immuno-oncology, oncology, and respiratory diseases.

Get a free copy of the Zacks research report on Ablynx Nv (ABLYF)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Ablynx Nv Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ablynx Nv and related companies with MarketBeat.com's FREE daily email newsletter.